Member Info for Hurst10

President Macron hosting press conference at 17.00 UK time.
Lockdown ahead.
UK borders compulsory tests, Avacta tests manufacturing trucks ready, to set off,PRE Easter CE announcement.

House broker gone best bid and highest offer price!
Clearly they want stock

very interesting development in the Radioligand market with Novartis diving even deeper into radioligands, notching licensing deal with iTheranostics for multiple compounds.
Novartis were quoted:
We continue to invest in radioligand therapy as one of the four unique platforms of Novartis Oncology. We believe working across multiple approaches is the key to reimagining cancer care,” said Susanne Schaffert, PhD, President, Novartis Oncology. “FAP is an exciting target and these agents are a great fit with our radioligand therapy pipeline, which we are actively investigating across multiple tumor types. We believe this technology has the potential to transform many patients’ lives.”
Well,this only highlights how attractive the JV that Avacta made with PointBiopharma was earlier this year and the huge commercial opportunity this is going to be.
The radiopharmaceutical market is expected to grow to $15 billion by 2025 and there is a substantial opportunity to grow much faster if safety and tolerability of these effective treatments can be improved. POINT Biopharma is a clinical-stage pharmaceutical company focused on developing radioligands2 as precision medicines for the treatment of cancer.
Remember POINT Biopharma is coming to Nasdaq via SPAC, where one of the key investors is Johnson&Johnson,this interesting JV with POINT Biopharma will highlight how valuable Avacta’s assets are and with it’s Precision Platform and FAP activated Radio-pharmaceuticals, you could see the majors seeking closer cooperation with Avacta.

The deposit order from UK Government already with manufacturers as per RNS, the full order for this batch is £750 mill, plenty of follow up orders in the UK alone! The actual LFT’s are in trucks ready to be shipped, one would have thought and once LFT test being given the ?, Avacta will be on the road, being delivered.Revised EPS forecast and target price !!
The US buyers will be all over this one, once again.

The MM’s are having a laugh, making sure all the “ loose” holders are off loading their shares, so they can pick it up and sit on them till RNS and pick up £2 on the announcement.
Watch out for further MSCI Blackrock related shareholdings !!

Keep buying

Covid: Secret filming exposes contamination risk at test results lab https://www.bbc.co.uk/news/uk-56556806

Almost a million post market prints, all buys so far

With Europe falling apart, the demand for daily testing will be substantial and the UK.
+ 150 mill a month for starters!
With eps margins of 35% , that is how we get to 565 for openers.
Monday price back at 265-70
Have a good week end
Enjoy the rugby

Yep, got US buyer all over it

Just a reminder of what the actually said recently and why an expected CE approval is due within days.
Note the company is talking about being in conversation with UK and overseas customers!

“In the UK, the Department of Health and Social Care is a potential customer and partner in the roll out of such a validated test.
“While Avacta continues to be in dialogue with the department, and with other organisations in the UK and abroad, with a view to future supply of its rapid antigen test, it is prioritising the full clinical validation of its nasal swab-based SARS-CoV-2 rapid antigen test as a prerequisite for CE marking and broad commercialisation.”
Avacta said it would update the market through the appropriate channels as it reached significant commercial and technical milestones.

Just out from US professors:

We also don’t know how long the immunity that vaccines provide lasts. In fact, many experts expect Covid-19 vaccine boosters will be necessary (vaccine makers are already preparing for this). Continuous testing and monitoring of emerging variants will help us determine what those boosters should protect against.

Germany requires negative COVID test from France

Ref border test
This mandatory Covid test will be used across Europe apparently

Lorry drivers entering UK to face mandatory Covid tests
Charles HymasHOME AFFAIRS EDITOR
ALL hauliers entering England face a mass testing regime to combat the threat of new Covid variants from the Continent, despite fears it could disrupt food supplies.

Ministers are to scrap exemptions for all lorry drivers, border officials and other specialist workers entering the country and replace them with mandatory “bespoke” tests to prevent variants reaching the UK, particularly from France.

image
It came as the NHS downgraded the national Covid alert from four to three after a “sharp decrease” in hospital admissions reduced the pressure faced by the health service. Meanwhile last night, EU leaders shot down Ursula von der Leyen’s plans to give Brussels power to block vaccine exports to the UK. The hauliers scheme, to be announced as early as this weekend, is expected to require hauliers to take the lateral flow tests when they are in the UK rather than at the border in an attempt to avoid delays that could lead to supermarket shortages.

All lorry drivers staying longer than two days will be required to have a test within 48 hours and then every 72 hours. This would mean three tests on days two, five, and eight at one of the 39 testing sites across the UK.

It will be enforced through fines similar to the £2,000 penalties that travellers face if they fail to test on days two and eight during home quarantine. Ministers may give industry seven days to prepare. “The potential impact is hard to quantify but there is a concern that an inbound testing regime will introduce an additional burden that could cause significant points of friction,” said a government source.

“There is a worry that it will upset hauliers who are grumpy post-Brexit. There are concerns about delivering to supermarkets because of any additional delays.”

Border Force staff involved in cross-Channel work have been told they will also have to be tested three times a week. It is thought there will be similar arrangements for other workers who are currently exempt from travel restrictions, including train and ferry staff.

It comes amid growing concerns over the third wave sweeping Europe with the Government’s scientific advisers most worried about the South African variant said to account for up to 10 per cent of cases in France.

The new testing regime – expected to cover all hauliers from any country outside the Common Travel Area – is being introduced before any decision to put France on the “red list”. This would require travellers to quarantine in hotels at a cost of £1,750 per person.

France this week lifted its requirement for all hauliers leaving the UK to present a negative Covid test, which was introduced in December amid its fears over the Kent variant, now blamed for the surge in cases on the Continent.

It is understood ministers were wary of adopting a similar scheme in reverse – requiring hauliers to test in France before arrival in England – beca

Interesting interview with Ceo of Moderna and their new JV with Astra Zeneca on the MRNA technology,creating new blood vessels and the subject on Gene Theraphy

https://www.forbes.com/sites/leahrosenbaum/2021/03/24/whats-next-for-moderna-post-covid-19-ceo-stephane-bancel-details-mrna-pipeline/

https://www.forbes.com/sites/leahrosenbaum/2021/03/24/whats-next-for-moderna-post-covid-19-ceo-stephane-bancel-details-mrna-pipeline/

Another key person Avacta will deal with, as part of the Government contract, which Avacta is about to receive,once the imminent CE approval goes live.Business Secretary Kwasi Kwarteng was recently quoted:Keeping workers safe is absolutely crucial and businesses have been working incredibly hard to prioritise the health of their staff and customers during this difficult timeMore employers sign up to rapid testing to protect workforceDozens of public and private sector employers are now offering rapid testing to those without symptoms.Expansion of testing will find more positive cases, keeping key workers from unknowingly passing on the virus and protecting vital services.To support this national effort, government departments are working in partnership with NHS Test and Trace to support businesses and public sector bodies to implement rapid testing, including organisations operating in the food, manufacturing, energy and retail sectors, and within the public sector including job centres, transport networks, and the military.

70-5

We believe these combined efforts will further expand the availability of tests authorized for screening asymptomatic individuals, including OTC use, help bolster existing and new testing programs and increase consumer access to testing.

Brazil the highest daily number this year and India facing double mutant

New guide lines from the FDA:

New Guidelines from the FDA
Testing remains an important cornerstone of our nation’s fight against COVID-19. This includes schools, workplaces, communities and other locations using testing to screen asymptomatic individuals who may still spread the virus. Screening involves testing asymptomatic individuals who do not have known or suspected exposure to COVID-19 in order to make individual decisions, such as whether an individual should participate in an activity, based on the test results.
First, the FDA issued a new supplemental template for test developers seeking emergency use authorization (EUA) of certain tests for screening with serial testing. Serial testing involves testing the same individual multiple times within a few days, and can increase chances of detecting asymptomatic infection that might not always show up with a single test. CDC recommends serial testing at least once per week, along with other mitigation measures, such as masking and social distancing, to reduce disease transmission. This template applies to developers of molecular and antigen tests, for use in serial testing programs, as well as at-home tests for use in a serial manner outside of a testing program, intended to detect SARS-CoV-2 from individuals without symptoms or other epidemiological reasons to suspect COVID-19 infection. This includes tests conducted in any location, including in a laboratory, at the point-of-care (POC), or even places such as a person’s home or certain non-traditional sites such as offices, sporting venues, airports, schools, etc.
We believe this effort will pave the way for further expanding the availability of tests authorized for screening asymptomatic individuals, help bolster existing and new testing programs and increase consumer access to testing.